Du Hengrui, Wang Haochen, Chen Yuxiang, Zhou Xixi
Department of Gastrointestinal surgery, Tengzhou Central People's Hospital, Tengzhou, 277500, China.
Department of Interventional Radiology, Jining First People's Hospital, Jining, 272000, China.
Sci Rep. 2025 May 31;15(1):19126. doi: 10.1038/s41598-025-03920-w.
Colon adenocarcinoma (COAD) is one of the most prevalent malignancies worldwide and its prognosis is extremely poor. Angiogenesis has been linked to clinical outcomes, tumor progression, and treatment sensitivity. However, the role of angiogenesis in the COAD microenvironment and its interaction with immunotherapy remains unclear. In this study, an integrative machine learning approach, including ten algorithms, was used to construct a prognostic consensus angiogenesis-related signature (CARS) for COAD. The optimal CARS constructed using the RSF + StepCox [forward] algorithm had superior performance for clinical prognostic prediction and served as an independent risk predictor for COAD. Patients in the low-CARS group, characterized by immune activation, elevated tumor mutation/neoantigen burden, and greater responsiveness to immunotherapy, had a superior prognosis. Patients in the high-CARS group exhibited a poor prognosis with higher angiogenesis activity and immunosuppressive status, indicating lower immunotherapy benefits. However, axitinib and olaparib may be promising treatment options for such patients. Taken together, we constructed a prognostic CARS that provides prognostic stratification and elucidates the characteristics of the tumor microenvironment, which might guide the selection of personalized treatments for patients with COAD.
结肠腺癌(COAD)是全球最常见的恶性肿瘤之一,其预后极差。血管生成与临床结局、肿瘤进展和治疗敏感性有关。然而,血管生成在COAD微环境中的作用及其与免疫治疗的相互作用仍不清楚。在本研究中,采用包括十种算法的综合机器学习方法,构建了COAD的预后一致性血管生成相关特征(CARS)。使用RSF + StepCox[向前]算法构建的最佳CARS在临床预后预测方面具有卓越性能,可作为COAD的独立风险预测指标。低CARS组患者具有免疫激活、肿瘤突变/新抗原负担增加以及对免疫治疗反应更强的特征,预后较好。高CARS组患者预后较差,血管生成活性较高且处于免疫抑制状态,表明免疫治疗获益较低。然而,阿昔替尼和奥拉帕尼可能是这类患者有前景的治疗选择。综上所述,我们构建了一个预后CARS,它提供预后分层并阐明肿瘤微环境的特征,这可能指导COAD患者个性化治疗的选择。